Mission Wealth Management LP Has $449,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Mission Wealth Management LP reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 23.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,815 shares of the medical instruments supplier’s stock after selling 545 shares during the quarter. Mission Wealth Management LP’s holdings in Becton, Dickinson and Company were worth $449,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BDX. Norges Bank purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $761,798,000. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares in the last quarter. Cooke & Bieler LP grew its holdings in shares of Becton, Dickinson and Company by 117.1% during the 4th quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock valued at $173,347,000 after acquiring an additional 383,485 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Becton, Dickinson and Company by 880.8% during the 4th quarter. First Trust Advisors LP now owns 294,082 shares of the medical instruments supplier’s stock valued at $71,706,000 after acquiring an additional 264,097 shares in the last quarter. Finally, Veritas Asset Management LLP grew its holdings in shares of Becton, Dickinson and Company by 13.3% during the 4th quarter. Veritas Asset Management LLP now owns 2,183,266 shares of the medical instruments supplier’s stock valued at $532,346,000 after acquiring an additional 255,914 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold 8,615 shares of company stock valued at $2,033,381 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX traded down $1.08 during trading hours on Friday, reaching $227.76. 617,155 shares of the company traded hands, compared to its average volume of 1,111,338. The stock’s fifty day moving average is $233.96 and its 200 day moving average is $237.51. The stock has a market cap of $65.82 billion, a P/E ratio of 50.17, a price-to-earnings-growth ratio of 2.00 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a 1-year low of $224.00 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.86 earnings per share. Equities research analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.67%. The ex-dividend date was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Evercore ISI decreased their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, Barclays upped their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.86.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.